← Back to Search

Taxane

Chemotherapy + Filgrastim for Advanced Lung Cancer

Phase 2

Waitlist Available

Research Sponsored by Amgen

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologically or cytologically confirmed stage IIIB or IV non-small cell lung cancer

No symptomatic brain metastases

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well giving chemotherapy drugs together with filgrastim works in treating patients with stage IIIB or stage IV non-small cell lung cancer.

Who is the study for?

Adults over 18 with stage IIIB or IV non-small cell lung cancer can join this trial. They must have a good performance status, controlled blood pressure and heart conditions, no recent heart attacks, and not be pregnant. Participants need normal kidney and liver function tests, no diabetes complications or active infections, and they should agree to use contraception if fertile.Check my eligibility

What is being tested?

The trial is testing the effectiveness of combining two chemotherapy drugs (Docetaxel and Vinorelbine) with Filgrastim—a drug that boosts white blood cells—to see if it helps patients better recover from chemo side effects while fighting advanced lung cancer.See study design

What are the potential side effects?

Chemotherapy may cause nausea, fatigue, hair loss, increased risk of infection due to low blood counts; Filgrastim might lead to bone pain or pain at the injection site. Side effects vary among individuals.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My lung cancer is confirmed to be at an advanced stage (IIIB or IV).

Select...

I do not have any symptoms from brain metastases.

Select...

My liver tests are within normal limits.

Select...

I am over 18 years old.

Select...

I am mostly independent and can care for myself.

Select...

My creatinine level is 2.0 mg/dL or lower.

Select...

My heart condition is stable, and it's been over 6 months since my last heart attack.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 7Eligibility criteria met

Find a Location

Who is running the clinical trial?

AmgenLead Sponsor

1,370 Previous Clinical Trials

1,377,688 Total Patients Enrolled

Barbara Allen, DVM, MBA, PharmDStudy ChairAmgen

Media Library

Docetaxel (Taxane) Clinical Trial Eligibility Overview. Trial Name: NCT00006215 — Phase 2

Lung Cancer Clinical Trial 2023: Docetaxel Highlights & Side Effects. Trial Name: NCT00006215 — Phase 2

Docetaxel (Taxane) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00006215 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this medicinal approach endorsed by the FDA?

"Based on a 1-3 scale, our team at Power gave this treatment an overall safety rating of 2. This is because Phase 2 trials have some evidence to demonstrate safety but no data exists yet for its efficacy."

Answered by AI

Is enrollment still available for this research trial?

"According to clinicaltrials.gov, this medical study is no longer recruiting and has not been updated since December 18th 2013. However, there are still 1,628 other active trials seeking participants right now."

Answered by AI

Are there multiple locations in the US that are currently conducting this clinical research?

"Currently, there are 19 medical centres enrolled in this trial. Examples include Valhalla, Independence and Kettering. It is recommended that those wishing to participate should select the closest clinic to reduce their travelling obligations."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

1999. "Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00006215.

All > Lung > Sclc